Immunome, Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
IMNM · Price history
Price at last available close
$18.29
−$3.22 (-14.97%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Immunome, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.
How they make money
Immunome is a biotechnology company that generates revenue primarily through research and development collaborations and licensing agreements for its proprietary antibody-drug conjugate (ADC) and oncology platforms. The company focuses on discovering and developing targeted cancer therapies, intending to build internal commercial infrastructure while exploring strategic partnerships to monetize its pipeline assets.
Products & services
The company develops a pipeline of targeted oncology therapies, including antibody-drug conjugates (ADCs) such as IM-3050 and the clinical-stage program varegacestat, aimed at treating various cancers.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Third-party diagnostic radiotracer suppliers — Suppliers of diagnostic radiotracers required for the initiation of the IM-3050 Phase 1 clinical study.Source
Business relationships & partnerships
- Ayala Pharmaceuticals — Asset purchase agreement under which Immunome acquired the AL101 and varegacestat programs.Source
Strengths
Company-specific research
Questions worth answering for IMNM
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving IMNM's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can IMNM fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is IMNM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for IMNM to reach sustainable profitability?
- •What future growth or profitability would be needed to justify IMNM's current valuation?
Essential Investment Snapshot
Market Cap
$2.16B
P/E Ratio
-8.5
EPS
$-2.54
52-Week High
$30.06
52-Week Low
$11.25
Beta
2.13
Analyst Target
$35.00
Shares Outstanding
87.4M
Total Debt
$4.6M
Dividend
No current dividend
Liquidation Value / Share
$6.01
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on IMNM.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary antibody-drug conjugate (ADC) technology platform.
- +Strong cash position to fund operations into 2028.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Requirement for material additional staffing to execute business plans.
- −Risks related to discovery, development, and regulatory approval of product candidates.
- −Diluted weighted-average shares increased 30.2% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$18.29
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $6.9M | $9.0M | $14.0M | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $49.9M | $3.0M | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$49.9M | $4.0M | $9.0M | $14.0M | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $216.2M | $174.3M | $129.5M | $23.1M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $54.2M | $43.8M | $33.0M | $19.7M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $220.5M | $218.1M | $314.8M | $123.5M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$251.2M | -$209.4M | -$151.4M | -$28.0M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$270.5M | -$214.1M | -$305.8M | -$109.5M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$254.3M | -$212.4M | -$293.0M | -$106.8M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$254.3M | -$212.4M | -$293.0M | -$106.8M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.54 | $-2.43 | $-5.00 | $-5.38 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 113M | 87.35M | 58.64M | 19.84M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 113M | 87.35M | 58.64M | 19.84M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.65
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+10.8%
Cash Change
+51.3%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included EPS growth, cash levels. Pressure indicators included revenue growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 100.0%. EPS increased 30.0%. Cash increased 51.3%. Total debt increased 10.8%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
7
Smart Money
7
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
Rumor Mill · IMNM
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial